MSMaria A. Sullivan

Maria A. Sullivan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria A. Sullivan has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Uses of Coercion in Addiction Treatment: Clinical Aspects

    by Maria A. Sullivan, Florian Birkmayer, Beth K. Boyarsky, Richard J. Frances, John A. Fromson, Marc Galanter, Frances R. Levin, Collins Lewis, Edgar P. Nace, Richard T. Suchinsky, et al.

    Coerced or involuntary treatment comprises an integral, often positive component of treatment for addictive disorders. By the same token, coercion in health care raises numerous ethical, clinical, legal, political, cultural, and philosophical issues. In order to apply coerced care effectively, health care professionals should appreciate the indications, methods, advantages, and liabilities associated with this important clinical modality. An expert panel, consisting of the Addiction Committee of the Group for the Advancement of Psychiatry, listed the issues to be considered by clinicians in considering coerced treatment. In undertaking this task, they searched the literature using Pubmed from 1985 to 2005 using the following search terms: addiction, alcohol, coercion, compulsory, involuntary, substance, and treatment. In addition, they utilized relevant literature from published reports. In the treatment of addictions, coercive techniques can be effective and may be warranted in some circumstances. Various dimensions of coercive treatment are reviewed, including interventions to initiate treatment; contingency contracting and urine testing in the context of psychotherapy; and pharmacological methods of coercion such as disulfiram, naltrexone, and the use of a cocaine vaccine. The philosophical, historical, and societal aspects of coerced treatment are considered.


  • Management of relapse in naltrexone maintenance for heroin dependence

    by Maria A. Sullivan, Fatima Garawi, Adam Bisaga, Sandra D. Comer, Kenneth Carpenter, Wilfrid N. Raby, Stephen J. Anen, Adam C. Brooks, Huiping Jiang, Evaristo Akerele, et al.


  • Socially Sanctioned Coercion Mechanisms for Addiction Treatment

    by Edgar P. Nace, Florian Birkmayer, Maria A. Sullivan, Marc Galanter, John A. Fromson, Richard J. Frances, Frances R. Levin, Collins Lewis, Richard T. Suchinsky, John S. Tamerin, et al.

    Coercion as a strategy for treatment of addiction is an effective but often negatively perceived approach. The authors review current policies for involuntary commitments and explore coercive dimensions of treating alcohol and drug dependence in the workplace, sports, and through professional licensure. Gender‐specific issues in coercion are considered, including evidence for improved treatment retention among pregnant and parenting women coerced via the criminal justice system. Social security disability benefits represent an area where an opportunity for constructive coercion was missed in the treatment of primary or comorbid substance use disorders. The availability of third‐party funding for the voluntary treatment of individuals with substance use disorders has decreased. This unmet need, coupled with the evidence for positive clinical outcomes, highlights the call for implementing socially sanctioned mechanisms of coercion.


  • Predictors of Retention in Naltrexone Maintenance for Opioid Dependence: Analysis of a Stage I Trial

    by Maria A. Sullivan, Jami L. Rothenberg, Suzanne K. Vosburg, Sarah H. Church, Shara J. Feldman, Eva M. Epstein, Herbert D. Kleber, Edward V. Nunes

    Behavioral naltrexone therapy (BNT) was developed to address the shortcomings of naltrexone maintenance for opiate dependence and improve compliance by integrating several empirically validated methods, including the use of a significant other to monitor compliance, voucher incentives, and motivational techniques. An uncontrolled Stage I pilot trial (n = 47) of BNT was conducted. Baseline demographic and clinical variables were evaluated as predictors of retention with univariate tests. Significant predictors were entered together into a multiple regression model. Poorer (shorter) retention in treatment was associated with methadone use and higher average bags per day of heroin. Other variables that became non‐significant in multiple regression analysis included older age and depressive symptoms. Individuals with greater physiologic dependence and/or dependence on longer‐acting opiates are at higher risk to drop out from naltrexone maintenance and may require a more gradual detoxification and more intensive behavioral therapy aimed at enhancing initial compliance.


  • Current perspectives on smoking cessation among substance abusers

    by Maria A. Sullivan, Lirio S. Covey

    The prevalence of nicotine dependence among alcohol or other substance abusers is extremely high, and surveys have revealed that many patients in drug or alcohol treatment programs are interested in smoking cessation. However, smoking cessation has not been a traditional focus in clinical interventions for this population. Recent evidence from clinical trials among individuals abusing alcohol, marijuana, cocaine, or opioids have shown the following: 1) smokers with a past but not current history of alcohol dependence have a similar rate of success compared with non-alcoholic smokers; 2) tobacco abstinence does not increase alcohol relapse; 3) continued smoking adversely affects treatment for marijuana dependence; 4) patterns of cocaine and nicotine use are interrelated; 5) smoking cessation rates among opioid-dependent individuals are several times lower than in the general US population. Smoking cessation is indicated for substance dependent persons already in recovery and may protect against relapse to the illicit drug of abuse.


  • Attention Deficit/Hyperactivity Disorder and Substance Abuse

    by Maria A. Sullivan, Frances Rudnik‐Levin

    Abstract:Patterns of association between attention deficit hyperactivity disorder (ADHD) and substance‐use disorders are considered. Recent investigations have found that up to 50% of individuals with continuing ADHD symptoms have a substance‐use disorder. ADHD appears to represent an independent risk factor for substance abuse. We review clinical challenges posed by the diagnosis of ADHD in substance‐abusing populations. Nicotine dependence is also substantially more common among adults with ADHD (40%) than in the general population (26%). While several classes of substances of abuse may ameliorate various symptoms of ADHD, individuals with ADHD may also be vulnerable to substance use because of poor judgment or impulsive behavior in social settings. Evidence is reviewed from genetic studies examining the role of the dopamine D2 (DRD2) gene in the etiology of ADHD. The presence of ADHD may affect the course of adolescent substance abuse in several ways: predicting earlier age of onset, longer duration of substance‐use disorder, and progression of alcohol abuse to another drug‐use disorder. Individuals with ADHD have been noted to have a shorter interval between the onsets of drug abuse and drug dependence. Such individuals are also at greater risk for treatment failure, as their disruptive behaviors interfere with treatment access and response. Lastly, we review advances in pharmacotherapeutic agents used for treating ADHD and consider the impact of these interventions on comorbid substance‐use disorders. We suggest promising areas of focus for clinical research trials targeting the subpopulation of substance abusers with concurrent ADHD.